Kikuchi's disease (KD), or histiocytic necrotizing lymphadenitis, was initially described in Japan in 1972. In the following years, several series of cases involving patients of different ages, races, and geographic origins were reported, but pediatric reports have been rare. The etiology of KD is unknown, although a viral or autoimmune hypothesis has been suggested. The most frequent clinical ...

Background. Tuberculosis (TB) patients registered in the government clinics under the DOTS (Directly Observed Treatment, Short Course) program in Chennai city catering to about 4.3 million population. Objective. To estimate the pattern and overall costs incurred by the new patients (who have never had treatment for tuberculosis or have taken antituberculosis drugs for less than one month) regis...

To cite: Chadwick A, Thwaites V, Holland M, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2017219841 DESCRIPTION A Nigerian-born British national aged 24 years presented to our tuberculosis (TB) clinic after a positive, screening, quantiFERON blood test. She had been in the country for 12 years, had no known exposure to TB and no previous medical history....

Antituberculosis drug-induced hepatotoxicity is quite common. However, factors predicting its development are still controversial. The objective of the present study was to evaluate the role of certain factors (age and sex of the patient, alcoholism, chronic liver disease, hepatitis B virus carrier status, acetylator status, nutritional status and antituberculosis treatment (ATT) regimen) in pr...

BACKGROUND & OBJECTIVES Antituberculosis (anti-TB) drug induced hepatotoxicity (DIH) is the most common side effect leading to interruption of therapy. Wide variations have been found in the reported incidence of hepatotoxicity during short-course chemotherapy. Several risk factors for hepatotoxicity have been suggested in previous studies. We undertook a prospective case-control study to asses...

There are contrasting data in the literature about antituberculosis plasma drug concentrations in HIV-1-coinfected patients. We report the pharmacokinetics of rifampin, isoniazid, and pyrazinamide in a cohort of patients being treated for active tuberculosis, the majority of whom were coinfected with HIV-1 and had commenced antiretroviral therapy within 2 months of starting antituberculosis tre...

Worldwide resistance to antituberculosis drugs is jeopardising the control and eventually the elimination of tuberculosis (TB). Patients who are infected by Mycobacterium tuberculosis resistant to antituberculosis drugs, especially to both isoniazid and rifampicin and thus having multidrug-resistant (MDR) TB, need more complicated treatment that lasts longer and consists of a large number of dr...

commonly encountered adverse effect withantituberculosis treatment.6-8 Recent developments especially in the field of molecular biology have expanded our views on the understanding of drug-induced liver damage. 9,10 In this paper, we have attempted to summarise the current understanding of the pathogenetic mechanismsof DIH as it has been viewed from the laboratory bench and the bedsideimplicati...

Clofazimine, a member of the riminophenazine class, is one of the few antibiotics that are still active against multidrug-resistant Mycobacterium tuberculosis (M. tuberculosis). However, the clinical utility of this agent is limited by its undesirable physicochemical properties and skin pigmentation potential. With the goal of maintaining potent antituberculosis activity while improving physico...

The efficacy of isoniazid in the treatment of pulmonary tuberculosis stimulated the search for related drugs that might increase the effectiveness of antituberculosis therapy especially in those chronically ill patients in whom INH does not produce the desired effect or who are unable to tolerate it. Such a compound is cyanacethydrazide** which as its formula indicates is structurally related t...